ProfileJobs

Karyopharm Therapeutics

Suggest Edit
    • Healthcarebiotechdrug developmentoncologypharma

    Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other diseases. The Company is developing small molecule Selective Inhibitor of Nuclear Export (SINE), compounds that inhibits the nuclear export protein XPO1. Karyopharm is seeking the regulatory approval and commercialization of its lead drug candidate, selinexor (KPT-330), as a single orally administered agent in cancer indications with unmet clinical need, initially for hematologic malignancies. It is also advancing the clinical development of selinexor in multiple solid tumor indications. The Company has initiated three registration-directed trials in hematological cancers with selinexor and anticipates initiating a fourth registration-directed trial.

    Employee Rating

    3.1More
    TypeSubsidiary
    Parent CompanyBiogen
    HQNewton, US
    Founded2008
    Websitekaryopharm.com
    Karyopharm Therapeutics was founded in 2008 and is headquartered in Newton, US
    Report incorrect company information

    Viewing summary data as a guest

    Sign up for free to see all data

    Key People/Management at Karyopharm Therapeutics

    Michael Kauffman

    Michael Kauffman

    Chief Executive Officer &Board of Directors
    John McCartney

    John McCartney

    Senior Director, Product Leadership
    Brian Austad

    Brian Austad

    Vice President, Head of Pharmaceutical Sciences
    Dilara McCauley

    Dilara McCauley

    Vice President, Product Leadership
    Show more

    Karyopharm Therapeutics Office Locations

    Karyopharm Therapeutics has offices in Newton and München
    Newton, US (HQ)
    85 Wells Ave
    München, DE
    9 Franziska-Bilek-Weg
    Show all (2)
    Report incorrect company information

    Karyopharm Therapeutics Financials and Metrics

    Summary Metrics

    Founding Date

    		2008

    Total Funding

    		$248.7 m

    Investors

    		Delphi Ventures, New Leaf Venture Partners, Foresite Capital
    Karyopharm Therapeutics is a subsidiary of Biogen

    Karyopharm Therapeutics Revenue

    Karyopharm Therapeutics's revenue was reported to be $250 k in FY, 2015 which is a 9.2% increase from the previous period.
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

    Revenue

    		387.0k229.0k250.0k

    Revenue growth, %

    		(41%)9%

    General and administrative expense

    		5.9m15.9m21.6m23.9m24.9m48.8m

    R&D expense

    		28.5m60.1m97.7m86.9m107.3m161.4m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

    General and administrative expense

    		1.6m2.9m3.3m3.8m5.4m6.2m4.8m5.6m6.0m5.9m6.3m6.6m5.8m7.6m17.1m

    R&D expense

    		7.7m11.0m13.2m16.0m20.8m27.0m25.9m21.8m24.6m19.9m24.1m23.1m25.2m41.3m86.1m

    Operating expense total

    		9.3m13.9m16.5m19.8m26.2m33.2m30.7m27.3m30.5m25.8m30.3m29.8m31.1m48.9m103.2m

    EBIT

    		(9.3m)(13.7m)(16.4m)(19.7m)(26.1m)(33.0m)(30.6m)(27.3m)(30.5m)(25.7m)(30.3m)(29.8m)(31.1m)(38.9m)(73.3m)
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

    Cash

    		156.0m150.6m58.4m49.7m69.0m118.0m

    Accounts Receivable

    Inventories

    		2.0m2.0m2.0m2.1m

    Current Assets

    		158.0m207.8m177.6m131.6m148.4m334.6m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

    Cash

    		52.9m144.9m132.3m227.1m51.5m24.2m43.5m42.2m37.7m43.9m25.6m55.4m54.5m37.5m119.0m

    Current Assets

    		53.6m147.6m135.3m231.3m249.3m225.3m198.3m138.1m124.2m130.3m112.2m145.7m121.7m133.3m244.6m

    PP&E

    		246.0k322.0k604.0k2.7m3.3m3.2m3.7m3.3m3.2m3.0m2.7m2.5m2.3m2.5m2.6m

    Total Assets

    		55.9m149.3m137.7m235.2m292.0m263.3m237.0m192.1m170.9m183.6m155.4m185.8m163.8m146.4m256.6m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

    Net Income

    		(33.9m)(75.8m)(118.2m)(109.6m)(129.0m)(178.4m)

    Depreciation and Amortization

    		144.0k323.0k634.0k717.0k713.0k735.0k

    Inventories

    		(1.4m)(45.0k)(55.0k)(120.0k)

    Accounts Payable

    		664.0k4.5m(2.4m)945.0k909.0k(1.4m)
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

    Net Income

    		(21.8m)(13.7m)(30.1m)(49.8m)(26.1m)(58.8m)(30.4m)(27.1m)(30.2m)(82.6m)(29.9m)(59.3m)(89.9m)(38.5m)(72.1m)

    Depreciation and Amortization

    		106.0k85.0k191.0k292.0k537.0k363.0k539.0k169.0k353.0k

    Accounts Payable

    		673.0k1.7m362.0k7.0m(1.8m)4.6m4.1m4.1m(1.7m)4.2m(1.5m)(2.9m)(773.0k)(1.9m)

    Cash From Operating Activities

    		(20.2m)(22.5m)(38.7m)(48.3m)(64.4m)(46.4m)(68.2m)(34.7m)(72.3m)
    show all
    Show all financial metrics

    Karyopharm Therapeutics Operating Metrics

    FY, 2015

    Patents Issued

    		10
    Show all operating metrics
    Report incorrect company information

    Competitors

    Heidelberg Pharma
    Healthcare - Public
    MEI Pharma
    Healthcare - Public
    Oncopeptides
    Healthcare - Public
    Peloton Therapeutics
    Healthcare - Private
    Compare competitors

    Karyopharm Therapeutics Online and Social Media Presence

    Embed Graph
    Report incorrect company information

    Karyopharm Therapeutics News and Updates

    October 29, 2018

    Karyopharm Therapeutics Announces Closing of Additional $22.5 Million of 3.00% Convertible Senior Notes Due 2025 Pursuant to Exercise in Full of Initial Purchasers’ Option

    NEWTON, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it has issued an additional $22.5 million aggregate principal amount of its 3.00% convertible senior notes due 2025 (the “notes”) pursuant to t…
    October 26, 2018

    Karyopharm Therapeutics Announces Management Change

    August 03, 2018

    Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    NEWTON, Mass., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 196,500 shares of Karyopharm’s …
    May 07, 2018

    Reader Inquiry: Is Karyopharm Therapeutics A Buy After The Secondary Offering?

    Report incorrect company information

    Karyopharm Therapeutics Blogs

    February 21, 2019

    Karyopharm to Report Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019

    Karyopharm to Report Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019 Content Import Thu, 02/21/2019 - 07:08 Karyopharm to Report Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019 Feb 21, 2019 This release is a ba…
    February 07, 2019

    Karyopharm Announces FDA Advisory Committee Meeting to Review Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma Who Have Received At Least Three Prior Therapies

    NEWTON, Mass. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) is scheduled to review data supporting the
    January 17, 2019

    Tanya Lewis

    Tanya Lewis alfredo.macaba… Thu, 01/17/2019 - 09:23 Tanya Lewis Senior Vice President, Regulatory Affairs Tanya joined Karyopharm in October 2018 and is responsible for the company’s regulatory affairs strategy and operations. Tanya is a…
    January 02, 2019

    Karyopharm to Present at the 37th Annual J.P. Morgan Healthcare Conference

    NEWTON, Mass. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman , MD, PhD, Chief Executive Officer, will present at the 37 th Annual J.P. Morgan Healthcare Conference on Monday, January 7,
    December 03, 2018

    Karyopharm Reports Updated Selinexor Data from the Phase 2b STORM and Phase 1b/2 STOMP Studies in Relapsed/Refractory Multiple Myeloma at the American Society of Hematology 2018 Annual Meeting

    -- Oral Selinexor Achieves 26.2% Overall Response Rate in STORM Study, 4.4 Month Median Duration of Response, 8.6 Month Median Overall Survival and 15.6 Month Median Survival in Patients with MR or Better -- -- Once Weekly Oral Selinexor in Combination with Darzalex ® and Low Dose Dexamethasone
    October 11, 2018

    Karyopharm Therapeutics Announces Pricing of $150 Million of Convertible Senior Notes

    Karyopharm Therapeutics Announces Pricing of $150 Million of Convertible Senior Notes Content Import Thu, 10/11/2018 - 07:03 Karyopharm Therapeutics Announces Pricing of $150 Million of Convertible Senior Notes Oct 11, 2018 This release is a backfill from a Ne…
    Show more

     Karyopharm Therapeutics Frequently Asked Questions

    • When was Karyopharm Therapeutics founded?

      Karyopharm Therapeutics was founded in 2008.

    • Who are Karyopharm Therapeutics key executives?

      Karyopharm Therapeutics's key executives are Michael Kauffman, John McCartney and Brian Austad.

    • Who are Karyopharm Therapeutics competitors?

      Competitors of Karyopharm Therapeutics include Heidelberg Pharma, MEI Pharma and Oncopeptides.

    • Where is Karyopharm Therapeutics headquarters?

      Karyopharm Therapeutics headquarters is located at 85 Wells Ave, Newton.

    • Where are Karyopharm Therapeutics offices?

      Karyopharm Therapeutics has offices in Newton and München.

    • How many offices does Karyopharm Therapeutics have?

      Karyopharm Therapeutics has 2 offices.

    Need Data?

    Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

    Learn more